Kinetics of release of heparin from alginate hydrogel

被引:16
作者
McLennan, G [1 ]
Johnson, MS [1 ]
Stookey, KR [1 ]
Zhang, ZD [1 ]
Fife, WK [1 ]
机构
[1] Indiana Univ Hosp, Dept Radiol, Div Intervent Radiol, Indianapolis, IN 46202 USA
关键词
adventitia; alginate; blood vessels; stenosis or obstruction; drug delivery; heparin; intimal hyperplasia;
D O I
10.1016/S1051-0443(07)61344-X
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
PURPOSE: Injected sodium alginate may be a useful perivascular drug delivery vehicle. This study was performed to determine the release rates of heparin from sodium alginate hydrogels crosslinked with varying amounts of calcium gluconate, MATERIALS AND METHODS: Six hydrogels, composed of 0.16 mEq sodium alginate and 4,000 units unfractionated heparin, were cross-linked with calcium gluconate to yield ion equivalence (IE) ratios (calcium:alginate) of 0.2, 0.4, 0.58, 0.8, 1.0, or 1.2. Two milliliters of normal saline was placed on top of each gel and allowed to remain in contact for up to 10 days, At set time intervals, the amount of heparin in the eluent was determined with use of highperformance liquid chromatography, RESULTS: Gels with 0.2 and 0.4 IE were partially liquid at 24 hours; the other gels solidified within 10 minutes, The 0.58 IE gel was slowest to solidify but immobilized the most heparin and released heparin slowest over 10 days, At 10 days, between 5.5% and 9.8% of the heparin immobilized was retained in the gel. CONCLUSION: This hydrogel shows promise as a vehicle for in vivo perivascular heparin delivery. The 0.58:1 IE ratio hydrogel has slowest release rate and the greatest immobilization despite its longer cross-linking time.
引用
收藏
页码:1087 / 1094
页数:8
相关论文
共 37 条
[1]  
Bertrand OF, 1997, EUR HEART J, V18, P1385
[2]   Local drug delivery systems and prevention of restenosis [J].
Brieger, D ;
Topol, E .
CARDIOVASCULAR RESEARCH, 1997, 35 (03) :405-413
[3]  
BUDVARDI S, 1996, MERCK INDEX ENCY CHE
[4]  
Carr ME, 1996, THROMB HAEMOSTASIS, V75, P674
[5]   ANALYSIS OF HEPARINS BY SIZE-EXCLUSION AND REVERSED-PHASE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH PHOTODIODE-ARRAY DETECTION [J].
DEVRIES, JX .
JOURNAL OF CHROMATOGRAPHY, 1989, 465 (02) :297-304
[6]   The role of radiation therapy in the management of vascular restenosis. Part 1. Biologic basis [J].
Diamond, DA ;
Vesely, TM .
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 1998, 9 (02) :199-208
[7]   CONTRASTING EFFECTS OF THE INTERMITTENT AND CONTINUOUS ADMINISTRATION OF HEPARIN IN EXPERIMENTAL RESTENOSIS [J].
EDELMAN, ER ;
KARNOVSKY, MJ .
CIRCULATION, 1994, 89 (02) :770-776
[8]   PERIVASCULAR AND INTRAVENOUS ADMINISTRATION OF BASIC FIBROBLAST GROWTH-FACTOR - VASCULAR AND SOLID ORGAN DEPOSITION [J].
EDELMAN, ER ;
NUGENT, MA ;
KARNOVSKY, MJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (04) :1513-1517
[9]  
Engelberg H, 1996, PHARMACOL REV, V48, P327
[10]  
Fram DB, 1997, CATHETER CARDIO DIAG, V41, P275, DOI 10.1002/(SICI)1097-0304(199707)41:3<275::AID-CCD8>3.0.CO